EMEA-001798-PIP02-16

Key facts

Active substance
Enasidenib
Therapeutic area
Oncology
Decision number
P/0293/2017
PIP number
EMEA-001798-PIP02-16
Pharmaceutical form(s)
  • Film-coated tablet
  • Age-appropriate oral solid dosage form
Condition(s) / indication(s)
Treatment of acute myeloid leukaemia
Route(s) of administration
  • Oral use
  • Gastric use
Contact for public enquiries
Celgene Europe Ltd
Tel. +41  327298500
E-mail: medinfo.intl@celgene.com
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating
Average
3 ratings